H.C. Wainwright lowered the firm’s price target on Kezar Life Sciences to $7 from $20 and keeps a Buy rating on the shares. The firm reduced estimates to reflect the company’s near-term outlook and changing market dynamics.
H.C. Wainwright lowered the firm’s price target on Kezar Life Sciences to $7 from $20 and keeps a Buy rating on the shares. The firm reduced estimates to reflect the company’s near-term outlook and changing market dynamics.